RPRX
$58.60
$-0.06 (-0.10%)-0.10%
ClosedLoading chart...
IndexN/A
Market Cap25.98B
Enterprise Value25.02B
Income$0.24B
Sales$0.57B
EmployeesN/A
P/E11.16
P/S7.02
P/B2.58
P/C6.70
EV/EBITDA15.30
EV/SalesN/A
EPS (ttm)5.25
EarningsN/A
Gross Margin100.00%
Oper. Margin65.58%
Profit Margin32.42%
Volume1.54M
Shs Outstand0.44B
Change0.07%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B | $1.81B | $1.79B | $1.60B |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $230.84M | $0.00 | $0.00 | $0.00 |
| Gross Profit | $2.26B | $2.35B | $2.24B | $2.29B | $1.89B | $1.81B | $1.79B | $1.60B |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 89.12% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $971.13M | $862.40M | $1.93B | $858.75M | $296.12M | $-808.92M | $430.45M | $658.24M |
| Operating Income | $1.29B | $1.49B | $307.06M | $1.43B | $1.60B | $2.62B | $1.36B | $939.69M |
| Operating Margin | 57.10% | 63.37% | 13.73% | 62.49% | 75.17% | 144.59% | 76.02% | 58.81% |
| Net Income | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M | $2.35B | $1.38B | $1.21B |
| Net Margin | 37.95% | 48.20% | 1.91% | 27.07% | 45.94% | 129.45% | 76.76% | 75.72% |
| EPS (Basic) | $1.92 | $2.54 | $0.10 | $1.49 | $2.60 | $6.42 | $2.27 | $1.99 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B | $12.45B | $11.37B | $11.37B |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B | $6.31B | $6.82B | $6.90B |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $6.95B | $6.53B | $5.63B | $5.78B | $4.82B | $6.11B | $4.49B | $4.46B |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.95B | $6.53B | $5.63B | $5.78B | $4.82B | $6.11B | $4.49B | $4.46B |
| Total Liabilities & Stockholders Equity | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B | $12.45B | $11.37B | $11.37B |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $858.98M | $1.13B | $42.83M | $619.73M | $975.04M | $2.35B | $1.38B | $1.21B |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $2.77B | $2.99B | $2.14B | $2.02B | $2.03B | $1.67B | $1.62B | $1.42B |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswire Inc. Royalty Pharma Declares Second Quarter 2026 DividendBenzinga Zymeworks Appoints Kristin Stafford as Chief Financial OfficerGlobeNewswire Inc. Vera Therapeutics Appoints Christopher Hite to Board of DirectorsGlobeNewswire Inc. Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global PlatformGlobeNewswire Inc. Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through InnovationGlobeNewswire Inc. Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewswire Inc. Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewswire Inc.
Show 12 more stories
Royalty Pharma Announces Dividend IncreaseBenzinga Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars OvernightBenzinga What's Going On With Royalty Pharma Stock Wednesday?Benzinga Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential MilestonesBenzinga Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc. Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured NotesGlobeNewswire Inc. Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 MillionBenzinga Royalty Pharma Declares Third Quarter 2025 DividendBenzinga Royalty Pharma Completes the Acquisition of Its External ManagerBenzinga Royalty Pharma Announces Shareholder Approval of its External Manager AcquisitionBenzinga Royalty Pharma Declares Second Quarter 2025 DividendBenzinga Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty PharmaBenzinga
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Discover more
You may be interested in